Jon Blatchford
YOU?
Author Swipe
View article: Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post‐hoc analysis from <scp>EMPULSE</scp>
Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post‐hoc analysis from <span>EMPULSE</span> Open
Aims Patients hospitalized for acute heart failure (HF) could be enrolled in EMPULSE (NCT04157751) upon haemodynamic stabilization and between 24 h and 5 days after hospital admission. The timing of treatment initiation may influence the e…
View article: Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction – Results from the <scp>EMPULSE</scp> trial
Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction – Results from the <span>EMPULSE</span> trial Open
Aim The EMPULSE (EMPagliflozin in patients hospitalised with acUte heart faiLure who have been StabilizEd) trial showed that, compared to placebo, the sodium–glucose cotransporter 2 inhibitor empagliflozin (10 mg/day) improved clinical out…
View article: An audit of a general practices compliance with national recommendations for the avoidance of complications for type 2 diabetic patients
An audit of a general practices compliance with national recommendations for the avoidance of complications for type 2 diabetic patients Open
Introduction Each week, diabetes leads to more than 700 strokes, almost 600 heart attacks and more than 2000 instances of heart failure, in addition to being the single most common cause of chronic kidney disease in the UK.1 The NHS spends…
View article: Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from <scp>EMPULSE</scp>
Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from <span>EMPULSE</span> Open
Aims In patients hospitalized for acute heart failure (AHF) empagliflozin produced greater clinical benefit than placebo. Many patients with AHF are treated with mineralocorticoid receptor antagonists (MRAs). The interplay between empaglif…
View article: The win ratio method in heart failure trials: lessons learnt from <scp>EMPULSE</scp>
The win ratio method in heart failure trials: lessons learnt from <span>EMPULSE</span> Open
Aims The EMPULSE trial evaluated the clinical benefit of empagliflozin versus placebo using the stratified win ratio approach in 530 patients with acute heart failure (HF) after initial stabilization. We aim to elucidate how this method wo…
View article: Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial Open
Aims Effective and safe decongestion remains a major goal for optimal management of patients with acute heart failure (AHF). The effects of the sodium–glucose cotransporter 2 inhibitor empagliflozin on decongestion-related endpoints in the…
View article: Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the <scp>EMPULSE</scp> trial
Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the <span>EMPULSE</span> trial Open
Aim The sodium–glucose cotransporter 2 (SGLT2) inhibitor empagliflozin improved clinical outcomes in patients hospitalized for acute heart failure. In patients with chronic heart failure, SGLT2 inhibitors cause an early decline in estimate…
View article: Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial
Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial Open
Background: Patients hospitalized for acute heart failure experience poor health status, including a high burden of symptoms and physical limitations, and poor quality of life. SGLT2 (sodium-glucose cotransporter 2) inhibitors improve heal…
View article: Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the <scp>EMPULSE</scp> trial
Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the <span>EMPULSE</span> trial Open
Aims Treatment with sodium–glucose co‐transporter 2 (SGLT2) inhibitors improves outcomes in patients with chronic heart failure (HF) with reduced ejection fraction. There is limited experience with the in‐hospital initiation of SGLT2 inhib…
View article: Ivabradine drug utilization study in five European countries: A multinational, retrospective, observational study to assess effectiveness of risk‐minimization measures
Ivabradine drug utilization study in five European countries: A multinational, retrospective, observational study to assess effectiveness of risk‐minimization measures Open
Purpose This drug utilization study of ivabradine evaluated prescriber compliance with the new risk minimization measures (RMMs), communicated starting 2014 following preliminary results from the SIGNIFY study. Methods This was a multinati…
View article: Issue Information
Issue Information Open
Aims and Scope: For more than 50 years, clinical pharmacologists, clinical and pharmaceutical researchers, drug development specialists, physicians, nurses, and other medical professionals have relied on The Journal of Clinical Pharmacolog…
View article: Design and Rationale of the <scp>RE‐DUAL PCI</scp> Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting
Design and Rationale of the <span>RE‐DUAL PCI</span> Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting Open
Antithrombotic management of patients with atrial fibrillation ( AF ) undergoing coronary stenting is complicated by the need for anticoagulant therapy for stroke prevention and dual antiplatelet therapy for prevention of stent thrombosis …